Indeed, more and more evidence suggests that therapy resistance and relapse are mostly due to the survival of cancer cells presenting with the stemness phenotype, typically enriched in specialized microenvironmental niches, and that DLK1 can play a role in the regulation and maintenance of this phenotype. The gene discussed is DLK1; the disease is cancer.